PharmiWeb

Long-Term Effects of PectaSol-C Modified Citrus Pectin Against Biochemically Relapsed Prostate Cancer--Updated Results from a Phase IIb Clinical Trial

SANTA ROSA, Calif., Jan. 2, 2020 /PRNewswire/ -- Better Health Publishing—A multi-center Phase IIb clinical trial conducted in Israel, has been studying the effects of a dietary supplement, modified ...
ascopubs.org

Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a ...

The association between physician trust and prostate specific antigen screening: Implications for shared decision making. This is an ASCO Meeting Abstract from the 2018 Genitourinary Cancers Symposium ...
Business Wire

Modified Citrus Pectin Shows Significant Benefits in Biochemically Relapsed Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Conference on February 8, 2018 showed that 79 percent of study participants ...
ascopubs.org

Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results ...

Sexual function, quality of life, and cancer-related distress among prostate cancer survivors. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a ...